Antihistamine Use in Newborns (<28 Days)
Direct Recommendation
Second-generation antihistamines (cetirizine or loratadine) should NOT be used routinely in newborns under 28 days of age, as FDA approval and safety data begin only at 6 months for cetirizine; in the rare emergency of anaphylaxis, epinephrine is the only first-line treatment, with diphenhydramine 1–1.25 mg/kg serving solely as adjunctive therapy under direct medical supervision. 1, 2
Safety Evidence Against Routine Antihistamine Use
Between 1969 and 2006,41 deaths from antihistamines occurred in children under 2 years of age, with diphenhydramine responsible for 33 of these fatalities. 1, 2
The FDA and American Academy of Pediatrics explicitly recommend against over-the-counter cough and cold medications (including first-generation antihistamines) in children below 6 years due to lack of efficacy and serious toxicity risk. 3, 1
First-generation antihistamines cause significant CNS depression, anticholinergic effects, and performance impairment that cannot be eliminated even with bedtime-only dosing due to prolonged half-lives. 3
Age-Appropriate Antihistamine Options
For Infants 6–11 Months (NOT Newborns)
Cetirizine 0.25 mg/kg twice daily (approximately 2.5 mg BID) is the only antihistamine with prospective, randomized, double-blind, placebo-controlled safety data in infants as young as 6 months. 2, 4
In a controlled trial of 6–11 month-old infants, cetirizine showed no cardiac QT prolongation, no increase in adverse events versus placebo, and a trend toward fewer sleep disturbances. 4
Liquid formulations are strongly preferred because they provide easier administration and better absorption in young infants. 1, 2
For Infants 12–24 Months
Cetirizine 2.5 mg twice daily is recommended, with twice-daily dosing necessary due to rapid oral clearance in very young children. 5
Loratadine may be considered as an alternative, though dosing must be physician-directed in children under 2 years. 2
Emergency Management Algorithm for Newborns
Mild Allergic Symptoms (Few Hives, Mild Itching)
Identify and eliminate the trigger (formula, topical product, environmental allergen) rather than initiating pharmacotherapy. 1
Immediate referral to a pediatric allergist is indicated if symptoms are severe enough to warrant treatment, rather than empiric antihistamine use. 1
Moderate-to-Severe Symptoms (Diffuse Hives, Respiratory Involvement, Lip/Tongue Swelling)
Administer epinephrine 0.01 mg/kg intramuscularly (0.1 mg for a typical 4 kg newborn using 1:1000 concentration), repeat every 5–15 minutes if symptoms persist, and call emergency services immediately. 1
Diphenhydramine 1–1.25 mg/kg orally (approximately 5 mg for a 4 kg newborn) may be added as adjunctive therapy ONLY under direct hospital supervision, never as monotherapy. 1
Epinephrine is the only first-line treatment; antihistamines are purely adjunctive and must never replace or delay epinephrine administration. 1
Critical Pitfalls to Avoid
Never use diphenhydramine for routine allergic symptoms, as a sleep aid, or "to calm" a newborn—this is explicitly contraindicated by FDA labeling and carries fatal overdose risk. 1, 2
Avoid all OTC cough-and-cold combination products in newborns and infants, as they increase overdose risk from multiple active ingredients and medication errors. 3, 1
Do not prescribe intranasal antihistamines (azelastine, olopatadine) in newborns, as they are approved only for children ≥12 years. 2
Oral decongestants (pseudoephedrine, phenylephrine) must not be used in newborns due to severe neuropsychiatric effects and death risk. 2
When Antihistamines Are Contraindicated in Newborns
Oral H1-antihistamines should NOT be administered to prevent wheezing or asthma in infants with atopic dermatitis or family history of allergy, as side effects outweigh uncertain preventive benefits. 1
For suspected food allergy (e.g., dairy), maternal dietary elimination (if breastfeeding) or hypoallergenic formula substitution is first-line, not antihistamines. 1
Comparative Safety: Second- vs. First-Generation Agents
Second-generation antihistamines (cetirizine, loratadine, desloratadine, fexofenadine, levocetirizine) have markedly superior safety profiles with very low rates of serious adverse events in young children. 1, 2
First-generation antihistamines impair psychomotor performance, cognitive function, and driving ability even without subjective awareness of sedation, with effects persisting beyond bedtime dosing. 3
Cetirizine may cause mild sedation (13.7% vs. 6.3% placebo in patients ≥12 years, lower in younger children), but this risk is far less than first-generation agents. 5, 6
Strength of Evidence Summary
| Recommendation | Evidence Level | Source |
|---|---|---|
| Avoid routine antihistamines in newborns | High (FDA/AAP guideline) | [1,2] |
| Cetirizine safety in 6–11 month infants | High (RCT) | [4] |
| Diphenhydramine mortality data | Strong observational | [1,2] |
| Epinephrine first-line for anaphylaxis | High (expert consensus) | [1] |